Ruxolitinib inhibits poly(I:C) and type 2 cytokines‐induced CCL5 production in bronchial epithelial cells: A potential therapeutic agent for severe eosinophilic asthma

RATIONALE: Severe eosinophilic asthma is characterized by airway eosinophilia and corticosteroid‐resistance, commonly overlapping with type 2 inflammation. It has been reported that chemokine (C‐C motif) ligand 5 (CCL5) is involved in the exacerbation of asthma by RNA virus infections. Indeed, treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Sada, Mitsuru, Watanabe, Masato, Inui, Toshiya, Nakamoto, Keitaro, Hirata, Aya, Nakamura, Masuo, Honda, Kojiro, Saraya, Takeshi, Kurai, Daisuke, Kimura, Hirokazu, Ishii, Haruyuki, Takizawa, Hajime
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127547/
https://www.ncbi.nlm.nih.gov/pubmed/33534941
http://dx.doi.org/10.1002/iid3.397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127547/
https://www.ncbi.nlm.nih.gov/pubmed/33534941
http://dx.doi.org/10.1002/iid3.397

Ejemplares similares